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Abstract Rationale: 3,4-Methylenedioxymethamphet-
amine (MDMA) is a widely abused illicit drug. In
animals, high-dose administration of MDMA produces
deficits in serotonin (5-HT) neurons (e.g., depletion of
forebrain 5-HT) that have been interpreted as neuro-
toxicity. Whether such 5-HT deficits reflect neuronal
damage is a matter of ongoing debate. Objective: The
present paper reviews four specific issues related to the
hypothesis of MDMA neurotoxicity in rats: (1) the ef-
fects of MDMA on monoamine neurons, (2) the use of
“interspecies scaling” to adjust MDMA doses across
species, (3) the effects of MDMA on established
markers of neuronal damage, and (4) functional
impairments associated with MDMA-induced 5-HT
depletions. Results: MDMA is a substrate for mono-
amine transporters, and stimulated release of 5-HT, NE,
and DA mediates effects of the drug. MDMA produces
neurochemical, endocrine, and behavioral actions in rats
and humans at equivalent doses (e.g., 1–2 mg/kg),
suggesting that there is no reason to adjust doses
between these species. Typical doses of MDMA causing
long-term 5-HT depletions in rats (e.g., 10–20 mg/kg)
do not reliably increase markers of neurotoxic damage
such as cell death, silver staining, or reactive gliosis.
MDMA-induced 5-HT depletions are accompanied by a
number of functional consequences including reduc-
tions in evoked 5-HT release and changes in hormone
secretion. Perhaps more importantly, administration of
MDMA to rats induces persistent anxiety-like behaviors
in the absence of measurable 5-HT deficits.
Conclusions: MDMA-induced 5-HT depletions are
not necessarily synonymous with neurotoxic damage.
However, doses of MDMA which do not cause long-
term 5-HT depletions can have protracted effects on
behavior, suggesting even moderate doses of the drug
may pose risks.
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy)
is an illicit drug used by young adults in the US, Europe,
and elsewhere. The appeal of MDMA is related to its
unique profile of psychotropic actions, which includes
amphetamine-like stimulant effects, coupled with feelings
of increased emotional sensitivity and closeness to others
(Liechti and Vollenweider 2001; Vollenweider et al. 1998).
MDMA misuse among children and adolescents is wide-
spread in the US (Landry 2002; Yacoubian 2003); a recent
sampling of high school students found 10% of 12th
graders reported using MDMA at least once (Banken
2004). MDMA-related medical complications have risen
more than 20-fold in recent years, consistent with increas-
ing popularity of the drug. Serious adverse effects of
MDMA intoxication include cardiac arrhythmias, hyper-
tension, hyperthermia, serotonin (5-HT) syndrome, hypo-
natremia, liver problems, seizures, coma, and, in rare cases,
death (Schifano 2004). Accumulating evidence indicates
that long-term MDMA abuse is associated with cognitive
impairments and mood disturbances, which can last for
months after cessation of drug intake (Morgan 2000;
Parrott 2002). Despite the risks of illicit MDMA use, some
clinicians believe the drug may have therapeutic potential
in the treatment of psychiatric disorders, such as post-
traumatic stress disorder, and clinical studies with MDMA
are underway (Doblin 2002). It is worth noting that
MDMA has been administered to human subjects in con-
trolled research settings, and few side effects are observed
under these circumstances (Harris et al. 2002; Mas et al.
1999).
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evaluate the pharmacology and toxicology of MDMA and
related compounds. In this review, we will examine four
topics related to the hypothesis of MDMA-induced 5-HT
neurotoxicity in rats: (1) the effects of MDMA on mono-
amine neurons, (2) the use of interspecies scaling to extra-
polate doses of MDMA across species, (3) the effects of
MDMA on established markers of neurotoxic damage, and
(4) the functional impairments associated with MDMA-
induced 5-HT depletions. The review will focus on data
obtained from rats since most preclinical MDMA research
has been carried out in this animal model. Previously
published and new data from our laboratory at the National
Institute on Drug Abuse (NIDA) will be included to
supplement literature reports. Clinical findings will be
mentioned in specific instances to note comparisons
between rats and humans. All experiments in our labora-
tory utilized male Sprague–Dawley rats (Wilmington, MA,
USA) weighing 300–350 g. Rats were maintained in
facilities accredited by the American Association of the
Accreditation of Laboratory Animal Care, and procedures
were carried out in accordance with the Animal Care and
Use Committee of the NIDA Intramural Research Program
(IRP). Data from mice will not be considered here because
this animal species displays the unusual characteristic of
long-term DA depletions (i.e., DA neurotoxicity) in
response to MDMA, rather than long-term 5-HT depletions
observed in rats, nonhuman primates, and most other
animals [reviewed by Colado et al. (2004)]. Finally, the
present paper will not address possible molecular mecha-
nisms underlying MDMA-induced 5-HT deficits, as
several excellent reviews have covered this subject (Lyles
and Cadet 2003; Monks et al. 2004; Sprague et al. 1998).
Effects of MDMA on monoamine neurons
To address the topic of MDMA-induced 5-HT neurotox-
icity, the pharmacology of MDMA must be briefly
reviewed. Figure 1 shows that MDMA is a ring-substituted
analog of methamphetamine. Ecstasy tablets ingested by
humans contain a racemic mixture of (+) and (−) isomers of
MDMA, and both stereoisomers are known to be bioactive
(Johnson et al. 1986; Schmidt et al. 1987). Ecstasy tablets
often contain other psychoactive substances such as sub-
stituted amphetamines, caffeine, or ketamine, which can
contribute to the overall effects of the ingested preparation
(Parrott 2004). Upon systemic administration, N-demeth-
ylation of MDMA occurs via first-pass metabolism to yield
the ring-substituted amphetamine analog 3,4-methylene-
dioxyamphetamine (MDA) (de la Torre et al. 2004). Initial
studies carried out in the 1980s showed that MDMA and
MDA stimulate efflux of preloaded [
3H]5-HT, and to a
lesser extent [
3H]DA, in nervous tissue (Johnson et al.
1986; Nichols et al. 1982; Schmidt et al. 1987). Subsequent
findings revealed that MDMA interacts with monoamine
transporter proteins to stimulate non-exocytotic release of
5-HT, DA and norepinephrine (NE) in rat brain (Berger et
al. 1992; Crespi et al. 1997; Fitzgerald and Reid 1993).
Table 1 summarizes previously published data from our
laboratory showing structure–activity relationships for
stereoisomers of MDMA, MDA, and related drugs as
monoamine releasers in rat brain synaptosomes (Partilla et
al. 2000; Rothman et al. 2001; Setola et al. 2003). Like
other substrate-type releasers, MDMA and MDA bind to
plasma membrane monoamine transporters and are trans-
located into the cytoplasm. The ensuing transmitter release
occurs by a two-pronged mechanism: (1) transmitter
molecules exit the cell along their concentration gradients
via reversal of normal transporter function, and (2) cyto-
plasmic concentrations of transmitter are increased due to
drug-induced disruption of vesicular storage [reviewed by
Rothman and Baumann (2002) and Rudnick and Clark
(1993)]. As shown in Table 1, stereoisomers of MDMA
and MDA are substrates for 5-HT transporters (SERT), NE
transporters (NET) and DA transporters (DAT), with (+)
isomers exhibiting greater potency as releasers. In par-
ticular, (+) isomers of MDMA and MDA are much more
effective DA releasers than their corresponding (−)
isomers. It is noteworthy that (+) isomers of MDMA
and MDA are rather nonselective in their ability to
stimulate monoamine release in vitro. When compared to
amphetamine and methamphetamine, the major effect of
methylenedioxy ring substitution is enhanced potency for
5-HT release and reduced potency for DA release. For
example, (+)-MDMA releases 5-HT (EC50=70.8 nM)
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408about ten times more potently than (+)-methamphetamine
(EC50=736 nM), whereas (+)-MDMA releases DA
(EC50=142 nM) about six times less potently than (+)-
methamphetamine (EC50=24 nM).
Consistent with in vitro results, in vivo microdialysis
experiments demonstrate that MDMA increases extracel-
lular 5-HTand DA in rat brain, with effects on 5-HT being
greater in magnitude (Baumann et al. 2005; Gudelsky and
Nash 1996; Kankaanpaa et al. 1998; Yamamoto et al.
1995). Figure 2 depicts new data from our laboratory
showing the stimulatory effects of MDMA and MDA on
extracellular 5-HT and DA in rat nucleus accumbens. In
these experiments, i.v. injections of saline (0 dose) or drug
were administered to conscious male rats undergoing in
vivo microdialysis. Doses of 0.3 and 1.0 mg/kg were
chosen because these doses of MDMA are self-adminis-
tered by rats (Ratzenboeck et al. 2001; Schenk et al. 2003).
Dialysate samples were collected every 20 min beginning
2 h before injections until 2 h thereafter; samples
were assayed for 5-HT and DA by high-performance
liquid chromatography coupled to electrochemical detec-
tion (HPLC–ECD) as described elsewhere (Baumann and
Rutter 2003). Neurochemical data were converted to
percentage of control values based on three preinjection
control samples. The effects of MDMA and MDA are
depicted as peak effects, which were observed in the first
20 min after injection. Peak effect data were analyzed using
a one-way ANOVA (drug dose) followed by Duncan’s post
hoc test. MDMA caused significant increases in dialysate
5-HT [F2,15=19.47, P<0.001] and DA [F2,15=14.46,
P<0.01]. MDA caused similar increases in 5-HT
[F2,15=17.95; P<0.001] and DA [F2,15=7.69, P<0.01], but
appeared to be slightly more potent at releasing DA. Both
drugs produced elevations in 5-HT that were greater than
the corresponding effects on DA. For example, the 1 mg/kg
dose of MDMA produced a tenfold rise in 5-HT and a
twofold rise in DA.
Acute central nervous system (CNS) effects of MDMA
are mediated by the release of monoamine transmitters,
with the subsequent activation of presynaptic and postsyn-
aptic receptors [reviewed by Cole and Sumnall (2003) and
Green et al. (2003)]. As specific examples in rats, MDMA
suppresses 5-HT cell firing, evokes neuroendocrine secre-
tion, and stimulates locomotor activity. MDMA-induced
suppression of 5-HT cell firing in the dorsal and median
raphe involves activation of presynaptic 5-HT1A auto-
receptors by endogenous 5-HT (Gartside et al. 1997;
Sprouse et al. 1989). Neuroendocrine effects of MDMA
include secretion of prolactin from the anterior pituitary
Table 1 Profile of MDMA and related compounds as monoamine transporter substrates in rat brain synaptosomes
Drug 5-HT release EC50 (nM±SD) NE release EC50 (nM±SD) DA release EC50 (nM±SD)
(+)-Methamphetamine 736±45 12±0.7 24±2
(−)-Methamphetamine 4,640±240 29±3 416±20
(±)-MDMA 74.3±5.6 136±17 278±12
(+)-MDMA 70.8±5.2 110±16 142±6
(−)-MDMA 337±34 564±60 3,682±178
(+)-Amphetamine 1,765±94 7.1±1.0 25±4
(±)-MDA 159±12 108±12 290±10
(+)-MDA 99.6±7.4 98.5±6.1 50.0±8.0
(−)-MDA 313±21 287±23 900±49
The data are taken from Partilla et al. 2000, Rothman et al. 2001, and Setola et al. 2003. Details concerning in vitro methods can be found in
these papers. Substrate activity at SERT, NET, and DAT is reflected as release efficacy for the corresponding transmitter
Fig. 2 Effects of (±)-MDMA and (±)-MDA on extracellular levels
of 5-HT (top panel) and DA (bottom panel) in rat nucleus
accumbens. Male rats undergoing in vivo microdialysis received
i.v. injections of saline (0 dose) or drug, and dialysate levels of 5-
HT and DA were assayed by HPLC–ECD (Baumann and Rutter
2003). Data are expressed as the percentage of three pre-injection
baseline samples; each bar represents the mean±SEM peak effect
measured 20 min posttreatment, N=6 rats/group. Baseline levels of
5-HT and DAwere 0.17±0.01 and 1.31±0.05 pg/5 μl, respectively.
Asterisk denotes significance with respect to zero dose control
(P<0.05 Duncan’s)
409and corticosterone from the adrenal glands (Nash et al.
1988). Evidence indicates that these MDMA-induced
hormonal effects are mediated via postsynaptic 5-HT2
receptors in the hypothalamus, which are activated by
released 5-HT. MDMA elicits a unique profile of locomo-
tor effects, characterized by forward locomotion and ele-
ments of the 5-HT behavioral syndrome such as forepaw
treading, flattened body posture, and head weaving (Gold
et al. 1988; Slikker et al. 1989; Spanos and Yamamoto
1989). The complex motor effects of MDMA are depen-
dent upon monoamine release followed by activation of
multiple 5-HT and DA receptor subtypes in the brain
[reviewed by Bankson and Cunningham (2001); Geyer
(1996)].
Adverse effects of acute MDMA administration, includ-
ing cardiovascular stimulation and elevated body temper-
ature, are thought to involve monoamine release from
sympathetic nerves in the periphery or nerve terminals in
the CNS. MDMA increases heart rate and mean arterial
pressure in conscious rats (O’Cain et al. 2000); this
cardiovascular stimulation is likely mediated by MDMA-
induced release of peripheral NE stores, similar to the
effects of amphetamine (Fitzgerald and Reid 1994).
MDMA has weak agonist actions at α2-adrenoreceptors
and 5-HT2 receptors, which might influence its cardiac and
pressor effects (Battaglia and De Souza 1989; Lavelle et al.
1999; Lyon et al. 1986). Moreover, MDA is a potent
5-HT2B agonist and this property could contribute to
adverse cardiovascular effects (Setola et al. 2003). The
ability of MDMA to elevate body temperature is well-
characterized in rats (Dafters 1995; Dafters and Lynch
1998; Nash et al. 1988), and this response has been con-
sidered a 5-HT-mediated process. However, a recent study
by Mechan et al. (2002) provides convincing evidence that
MDMA-induced hyperthermia involves the activation of
postsynaptic D1 receptors by released DA.
The long-term adverse effects of MDMA on 5-HT
systems have attracted substantial interest because studies
in rats and nonhuman primates show that high-dose
MDMA administration produces persistent reductions in
markers of 5-HT nerve terminal integrity [reviewed by
Lyles and Cadet (2003); Sprague et al. (1998)]. Table 2
summarizes findings of investigators who first demonstrat-
ed that MDMA causes long-term (>1 week) inactivation of
tryptophan hydroxylase activity, depletions of brain tissue
5-HT, and reductions in SERT binding and function
(Battaglia et al. 1987; Commins et al. 1987; Schmidt
1987; Stone et al. 1987). These serotonergic deficits are
observed in various regions of rat forebrain, including
frontal cortex, striatum, hippocampus, and hypothalamus.
Immunohistochemical analysis of 5-HT in cortical and
subcortical areas reveals an apparent loss of 5-HT axons
and terminals in MDMA-treated rats, especially the fine-
diameter projections arising from the dorsal raphe nucleus
(O’Hearn et al. 1988). Moreover, 5-HTaxons and terminals
remaining after MDMA treatment appear swollen and
fragmented, suggesting structural damage.
Time-course studies indicate that MDMA-induced 5-HT
depletion occurs in a biphasic manner, with a rapid acute
phase followed by a delayed long-term phase (Schmidt
1987; Stone et al. 1987). In the acute phase, which lasts for
the first few hours after drug administration, massive
depletion of brain tissue 5-HT is accompanied by inacti-
vation of tryptophan hydroxylase. Twenty-four hours later,
tissue 5-HT recovers to normal levels but hydroxylase
activity remains diminished. In the long-term phase, which
begins within 1 week and lasts for months, marked
depletion of 5-HTis accompanied by sustained inactivation
of tryptophan hydroxylase and loss of SERT binding and
function (Battaglia et al. 1988; Scanzello et al. 1993). The
findings in Table 2 have been replicated by many inves-
tigators, and the spectrum of decrements is typically
described as 5-HT neurotoxicity. Most of the studies
designed to examine MDMA neurotoxicity in rats have
employed i.p. or s.c. injections of 10 mg/kg or higher,
either as single or repeated treatments. These MDMA
dosing regimens are known to produce significant hyper-
thermia, which can exacerbate 5-HT depletions caused by
the drug (Green et al. 2004; Malberg and Seiden 1998). All
of these experiments have involved administration of
MDMA that is not contingent on a specific behavior
and this factor could significantly influence effects of the
drug.
There are caveats to the hypothesis that MDMA pro-
duces 5-HT neurotoxicity. O’Hearn et al. (1988) showed
that high-dose MDMA administration has no effect on
5-HT cell bodies in the dorsal raphe, despite profound loss
of 5-HT in forebrain projection areas. Thus, the effects of
MDMA on 5-HT neurons are sometimes referred to as
“axotomy,” to account for the fact that perikarya are not
Table 2 Long-term effects of (±)-MDMA on 5-HT neuronal markers in rats
5-HT deficit Dose Survival
interval
Reference
Depletions of 5-HT in cortex, as measured by HPLC–ECD 10 mg/kg, s.c., single dose 1 week Schmidt (1987)
Depletions of 5-HT in forebrain regions as measured
by HPLC–ECD
10–40 mg/kg, s.c., twice daily,
4 days
2 weeks Commins et al.
(1987)
Reductions in tryptophan hydroxylase activity in forebrain regions 10 mg/kg, s.c., single dose 2 weeks Stone et al. (1987)
Loss of [
3H]-paroxetine-labeled SERT binding sites in forebrain
regions
20 mg/kg, s.c., twice daily,
4 days
2 weeks Battaglia et al.
(1987)
Deceased immunoreactive 5-HT in fine axons and terminals in
forebrain regions
20 mg/kg, s.c., twice daily,
4 days
2 weeks O’Hearn et al.
(1988)
410damaged (Molliver et al. 1990;O ’Hearn et al. 1988).
MDMA-induced reductions in 5-HT levels and SERT
binding eventually recover (Battaglia et al. 1988; Scanzello
et al. 1993), suggesting the possibility that 5-HT terminals
are not destroyed. Many drugs used clinically produce
effects that are similar to those produced by MDMA. For
instance, reserpine causes sustained depletions of brain
tissue 5-HT, yet reserpine is not considered a neurotoxin
(Carlsson 1976). Chronic administration of 5-HT selective
reuptake inhibitors (SSRIs), like paroxetine and sertraline,
leads to a marked loss of SERT binding and function
comparable to MDMA, but these agents are therapeutic
drugs rather than neurotoxins (Benmansour et al. 1999;
Frazer and Benmansour 2002). Finally, high-dose admin-
istration of SSRIs produces swollen, fragmented, and
abnormal 5-HT terminals, which are indistinguishable
from the effects of MDMA and other substituted amphet-
amines (Kalia et al. 2000).
The caveats mentioned above raise a number of
questions with respect to MDMA neurotoxicity. Of course,
the most important question is whether MDMA abuse
causes neurotoxic damage in humans. This complex issue
is a matter of ongoing debate, which has been addressed by
a number of recent papers (Gouzoulis-Mayfrank et al.
2002; Kish 2002; Reneman 2003). Clinical studies de-
signed to critically evaluate the long-term effects of
MDMA are hampered by a number of factors, including
comorbid psychopathology and polydrug abuse among
MDMA users. Animal models afford the unique opportu-
nity to evaluate the effects of MDMA without many of
these complicating factors, and the main focus here will be
to review the evidence pertaining to MDMA-induced 5-HT
neurotoxicity in rats.
“Interspecies scaling” and MDMA dosing regimens
A major point of controversy relates to the relevance of
MDMA doses administered to rats when compared to
doses taken by humans [see (Cole and Sumnall (2003)]. As
noted above, MDMA regimens that produce 5-HT de-
pletions in rats involve administration of single or multiple
injections of 10–20 mg/kg, whereas the typical amount of
MDMA abused by humans is one or two tablets of
80–100 mg or 1–3 mg/kg administered orally (Green et al.
2003; Schifano 2004). Based on principles of “interspecies
scaling,” some investigators have proposed that neurotoxic
doses of MDMA in rats correspond to recreational doses
in humans (Ricaurte et al. 2000). To critically evaluate
this claim, a brief discussion of interspecies scaling is
warranted.
The concept of interspecies scaling is based upon shared
biochemical mechanisms among eukaryotic cells (e.g.,
aerobic respiration), and it was initially developed to
describe variations in basal metabolic rate (BMR) between
animal species of different sizes [reviewed by White and
Seymour (2005)]. In the 1930s, Kleiber (1932) derived
what is now called the “allometric equation” to describe the
relationship between body mass and BMR. The generic
form of the allometric equation is: Y ¼ aWb , where Y is
the variable of interest, W is body weight, a is the
allometric coefficient, and b is the allometric exponent. In
the case where Y is BMR, b is accepted to be 0.75. West et
al. (2002) have shown that most biological phenomena
scale according to a universal quarter–power law, as
illustrated by the space-filling fractal networks of branch-
ing tubes used by the circulatory system.
Given that the allometric equation is grounded in
fundamental commonalities across organisms, it is not
surprising this equation can describe the relationship
between body mass and physiological variables, such as
BMR, heart rate, and circulation time [e.g., Noujaim et al.
(2004)]. Because circulation time and organ blood flow
strongly influence drug pharmacokinetics, the allometric
equation has been used in the medication development
process to “scale-up” dosages from animal models to man
[reviewed byMahmood (1999)]. In general, smaller animals
have faster heart rates and circulation times, leading to faster
clearance of exogenous drugs. However, this relationship
does not hold true for all classes of drugs, especially those
that are extensively metabolized (Lin 1998).
The most important variable to consider when examin-
ing therapeutic or adverse effects of any drug is the
concentration of bioactive compound reaching target tis-
sues. Tissue drug concentrations are governed by drug
absorption, distribution, metabolism, and elimination
(ADME) in a complex manner. Many factors such as
dose, route, species, strain, age, and gender can affect the
ADME profile of a given drug, thereby affecting tissue
concentrations. Campbell (1995) has described numerous
limitations of interspecies scaling to predict pharmacoki-
netic parameters in different species. In particular, the
allometric equation does not account for species-specific
variability in tissue uptake of substituted amphetamines, as
illustrated by the fact that brain-to-plasma ratios of the
5-HT releaser fenfluramine are 30–50 for the rat, yet <10
for humans. No studies have compared the brain tissue
uptake of MDMA in various animal models. Perhaps the
most problematic issue in extrapolating doses across
species is the unpredictable nature of drug metabolism,
which occurs chiefly in the liver [see Campbell (1996)].
Marked species differences in hepatic drug metabolism are
due to variations in expression and activity of cytochrome
P450 enzymes, which catalyze biotransformation reactions
(Lin 1995).
MDMA is extensively metabolized in humans, as
depicted in Fig. 3, and the major pathway of biotransfor-
mation involves: (1) O-demethylenation catalyzed by
cytochrome P450 2D6 (CYP2D6) and (2) O-methylation
catalyzed by catechol-O-methyltransferase (COMT) [re-
viewed by de la Torre et al. (2004)]. CYP2D6 and COMT
are both polymorphic in humans, and differential expres-
sion of CYP2D6 isoforms leads to interindividual varia-
tions in the metabolism of serotonergic medications (e.g.,
SSRIs) (Charlier et al. 2003). Interestingly, CYP2D6 is not
present in rats, which express a homologous but function-
ally distinct cytochrome P450 2D1 (Malpass et al. 1999;
Maurer et al. 2000). A minor pathway of MDMA
411biotransformation in humans involves N-demethylation
of MDMA to form MDA, which is subsequently
O-demethylenated and O-methylated. N-demethylation of
MDMA represents a more important pathway for rats when
compared to humans (de la Torre and Farre 2004). The
metabolism of MDMA and MDA generates a number of
metabolites, some of which may be active [e.g., Escobedo
et al. (2005); Forsling et al. (2002)]. Determining the
potential neurotoxic properties of the various metabolites
of MDMA is an important area of research [reviewed by
Baumgarten and Lachenmayer (2004); Monks et al.
(2004)].
To complicate matters further, de la Torre et al. (2000)
have shown that MDMA displays nonlinear kinetics in
humans such that administration of increasing doses, or
multiple doses, leads to unexpectedly high plasma levels of
the drug. Enhanced plasma and tissue levels of MDMA are
most likely related to auto-inhibition of MDMA metabo-
lism, mediated via formation of a metabolite–enzyme
complex that irreversibly inactivates CYP2D6 (Wu et al.
1997). Because MDMA displays nonlinear kinetics,
repeated drug dosing could produce serious adverse con-
sequences due to unusually high blood and tissue levels of
the drug (Parrott 2002; Schifano 2004). The existing
database of MDMA pharmacokinetic studies represents a
curious situation where clinical findings are well-docu-
mented, while preclinical data are lacking. Specifically,
few studies in animals have assessed the relationship
between pharmacodynamic effects and pharmacokinetics
of MDMA after administration of single or repeated doses
[but see Chu et al. (1996)]. No studies have systematically
characterized the nonlinear kinetics of MDMA in animal
models. Collectively, the available data demonstrate that
potential species differences in tissue drug uptake,
variations in metabolic enzymes and their activities, and
the phenomenon of nonlinear kinetics, preclude the use of
interspecies scaling to extrapolate MDMA doses between
animals and humans [reviewed by de la Torre and Farre
(2004)].
The uncertainties and limitations of allometric scaling
led us to investigate the method of “effect scaling” as an
alternative strategy for matching equivalent doses of
MDMA in rats and humans [see Winneke and Lilienthal
(1992)]. In this approach, the lowest dose of drug that
produces a specific pharmacological response is deter-
mined for rats and humans, and subsequent dosing
regimens in rats are calculated with reference to the
predetermined threshold dose. In the case of MDMA, this
strategy is simplified because CNS drug effects, such as
neuroendocrine and behavioral changes, have already been
investigated in different species. Theoretically, equivalent
drug effects in vivo should reflect similar drug concentra-
tions reaching active sites in tissue, suggesting that the
method of effect scaling can account for differences in
ADME across species (at least for low drug doses). Table 3
shows the doses of MDMA that produce comparable CNS
effects in rats and humans. Remarkably, the findings reveal
that doses of MDMA in the range of 1–2 mg/kg produce
pharmacological effects that are equivalent in both species.
It is noteworthy that MDMA is typically administered to
rats via the i.p. or s.c. route, whereas humans take the drug
orally. Given the similar effects of MDMA in rats and
humans at the same doses, it appears that drug bioavail-
ability is comparable after i.p., s.c., or oral administration
[e.g., Finnegan et al. (1988)], but verification of this
hypothesis awaits further investigation.
Administration of MDMA at i.p. doses of 1–3 mg/kg
causes marked elevations in extracellular 5-HT and DA in
rat brain, as determined by in vivo microdialysis (Baumann
et al. 2005; Gudelsky and Nash 1996; Kankaanpaa et al.
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4121998). The data from Fig. 2 illustrate that doses of MDMA
as low as 0.3 mg/kg i.v. stimulate a significant rise in
extracellular 5-HT in rat nucleus accumbens. Although it is
impossible to directly measure 5-HT and DA release in
living human brain, clinical studies indicate that subjective
effects of recreational doses of MDMA (1.5 mg/kg, p.o.)
involve transporter-mediated release of 5-HT (Liechti et al.
2000; Liechti and Vollenweider 2001). Nash et al. (1988)
showed that i.p. injections of 1–3 mg/kg of MDMA
stimulate prolactin and corticosterone secretion in rats, and
similar oral doses increase plasma prolactin and cortisol in
human drug users (Harris et al. 2002; Mas et al. 1999). The
dose of MDMA discriminated by rats and humans is
identical: 1.5 mg/kg, i.p. for rats (Glennon and Higgs 1992;
Oberlender and Nichols 1988; Schechter 1988) and 1.5 mg/
kg, p.o. for humans (Johanson et al. 2006). A few studies
have shown that rats will self-administer MDMA at doses
ranging from 0.25–1.0 mg/kg i.v., indicating these doses
possess reinforcing efficacy (Ratzenboeck et al. 2001;
Schenk et al. 2003). Wakonigg et al. (2003) demonstrated
that a single i.v. injection of 1 mg/kg MDMA serves a
powerful reinforcer in an operant runway procedure, and
MDMA displays similar reinforcing potency in Sprague–
Dawley and Long–Evans rat strains. Tancer and Johanson
(2003) reported that 1 and 2 mg/kg of MDMA have
reinforcing properties in humans that resemble those of (+)-
amphetamine. The findings summarized in Table 3 suggest
that there is no scientific justification for using interspecies
scaling to “adjust” MDMA doses between rats and
humans.
Based on this analysis, we devised an MDMA dosing
regimen in rats, which attempts to mimic binge use of
MDMA in humans. Male Sprague–Dawley rats weighing
300–350 g were double-housed in plastic cages, under
conditions of constant ambient temperature (22°C) and
humidity (70%) in a vivarium. In our initial studies, three i.
p. injections of 1.5 or 7.5 mg/kg MDMA were adminis-
tered, one dose every 2 h, to yield cumulative doses of 4.5
or 22.5 mg/kg. Control rats received saline vehicle
according to the same schedule. Rats were removed from
their cages to receive i.p. injections but were otherwise
confined to their home cages. The 1.5-mg/kg dose was
used as a low “behavioral” dose, whereas the 7.5-mg/kg
dose was used as a high “noxious” dose (i.e., a dose five-
fold greater than threshold). Our repeated dosing regimen
was designed to account for the common practice of
sequential dosing (i.e., “bumping”) used by human sub-
jects during rave parties (Parrott 2002). During the binge
dosing procedure, body temperatures were measured by
insertion of a thermometer probe into the rectum, and
5-HT-mediated behaviors were scored every hour. Rats
were decapitated 2 weeks after dosing, brain regions were
dissected, and tissue levels of 5-HT and DA were deter-
mined by HPLC–ECD as described previously (Baumann
et al. 2001). Neurochemical data were normalized to
percentage of saline control values for each brain region
examined. Data were analyzed using a one-way ANOVA
(MDMA dose), followed by Duncan’s post hoc test.
Figure 4 illustrates new data showing that our binge
MDMA dosing regimen increases core body temperature in
rats (F2,48=40.44, P<0.001). Specifically, repeated i.p.
doses of 7.5 mg/kg MDMA elicited persistent hyperther-
mia on the day of treatment, whereas doses of 1.5 mg/kg
did not. The 7.5-mg/kg dose caused temperature increases
that were about 2°C greater than control treatment. The
data in Fig. 5 demonstrate that binge MDMA treatment
significantly decreases tissue 5-HT levels in the frontal
cortex (F2,12=42.96, P<0.0001), striatum (F2,12=11.46,
P<0.001), and olfactory tubercles (F2,12=21.27,
P<0.0001) when assessed 2 weeks later. Post hoc tests
revealed that high-dose MDMA produced long-term
depletions of tissue 5-HT (∼50% reductions) in all three
regions examined, but the low-dose group had 5-HT
concentrations similar to saline controls. Transmitter de-
pletion was selective for 5-HT neurons since tissue DA
levels were unaffected. The magnitude of 5-HT depletions
depicted in Fig. 5 is similar to that observed by others
(Battaglia et al. 1987; Schmidt 1987; Stone et al. 1987).
Our findings demonstrate that repeated treatment with
behaviorally relevant doses of MDMA does not cause
acute hyperthermia or long-term 5-HT depletions. In
contrast, repeated administration of MDMA at a dose
that is fivefold higher than the behavioral dose causes both
of these adverse effects. The data are consistent with those
of O’Shea et al. (1998), who reported that high-dose
MDMA (10 or 15 mg/kg, i.p.) but not low-dose MDMA
(4 mg/kg, i.p.) causes acute hyperthermia and long-term
5-HT depletion in Dark Agouti rats.
Table 3 Comparative neurobiological effects of (±)-MDMA administration in rats and humans
CNS effect Dose in rats Dose in humans
In vivo release of 5-HT and DA 2.5 mg/kg, i.p. (Gudelsky
and Nash 1996); 1 mg/kg, s.c.
(Kankaanpaa et al. 1998)
1.5 mg/kg p.o.
a (Liechti et al. 2000;
Liechti and Vollenweider 2001)
Secretion of prolactin and glucocorticoids 1–3 mg/kg, i.p. (Nash et al. 1988) 1.67 mg/kg, p.o. (Mas et al. 1999);
1.5 mg/kg, p.o. (Harris et al. 2002)
Drug discrimination 1.5 mg/kg, i.p. (Oberlender and Nichols
1988; Schechter 1988).
1.5 mg/kg, p.o. (Johanson et al. 2006)
Drug reinforcement 1 mg/kg, i.v. (Wakonigg et al. 2003). 1–2 mg/kg, p.o.
b (Tancer and Johanson 2003)
aSubjective effects were attenuated by 5-HT uptake blockers, suggesting the involvement of transporter-mediated 5-HT release
bReinforcing effects were determined based on a multiple choice procedure
413Effects of MDMA on established markers
of neurotoxicity
Hallmark indicators of neurotoxicity include cell death,
silver positive staining (i.e., argyrophilia), and glial
cell hypertrophy (Baumgarten and Lachenmayer 2004;
O’Callaghan and Sriram 2005; Switzer 2000). Despite the
abundance of evidence showing that MDMA causes 5-HT
depletions, few studies have examined the effects of
MDMA on established markers of neurotoxic damage.
Indeed, some investigators have argued that based on 5-HT
abnormalities alone, one cannot infer the presence of
neurotoxicity (O’Callaghan and Miller 1993; Wang et al.
2004). Support for the hypothesis of MDMA-induced
axotomy relies heavily upon immunohistochemical analy-
sis of 5-HT levels, and the use of semiquantitative methods
could produce misleading results if not validated by other
means. For example, the MDMA-induced disappearance of
immunoreactive 5-HT in specific brain regions could
reflect depletion oftransmitter to alow level (i.e.,below the
level of detection) in intact axons and nerve terminals.
Thus, an alternative hypothesis consistent with available
data is that MDMA-induced deficits in 5-HT systems are
due to persistent adaptive changes in gene expression or
protein function, and these changes reflect a state of
metabolic quiescence or exhaustion, rather than neurotoxic
damage. Table 4 summarizes the findings from studies that
have examined the effects of MDMA on established
indicators of neurotoxic damage. All of the studies em-
ployed large doses of MDMA, either as single or repeated
injections, which cause hyperthermia and its associated
complications.
Silver staining methods are commonly utilized to
identify degenerating neuronal elements in the CNS
[reviewed by Switzer (2000)]. In particular, silver stains
are sensitive indicators of damage caused by neurotoxic
chemicals. Commins et al. (1987) examined the neurotoxic
potential of MDMA by using the Fink–Heimer procedure
to detect argyrophilic neuronal structures. In their study,
male Sprague–Dawley rats received single or multiple s.c.
injections of 80 mg/kg MDMA and were killed 15 to 48 h
later. Single doses of MDMA increased silver-positive
staining only in the frontoparietal cortex. Multiple doses
caused more extensive damage; degenerating nerve
terminals were found in the striatum, while degenerating
terminals, axons, and cell bodies were observed throughout
layers III and IV of the parietal cortex. In a comparable
study, Jensen et al. (1993) used the de Olmos cupric–silver
procedure to delineate areas of the brain damaged by
MDMA. Male Long–Evans rats received twice daily s.c.
injections of 25–150 mg/kg MDMA for 2 days and were
sacrificed 48 h thereafter. In this case, MDMA produced
dose-dependent increases in silver-positive staining in the
parietal cortex, with some irregular staining in the striatum
Fig. 4 Acute effects of (±)-MDMA on core body temperature in
rats. Male rats received three i.p. injections of 1.5 or 7.5 mg/kg
MDMA, one dose every 2 h (i.e., injections at 0, 2, and 4 h). Saline
was administered on the same schedule. Core temperature was
recorded via insertion of a rectal thermometer probe every 2 h. Data
are mean±SEM for N=5 rats/group. Asterisk denotes significance
with respect to saline-injected control at each time point (P<0.05
Duncan’s)
Fig. 5 Long-term effects of (±)-MDMA on tissue levels of 5-HT
(top panel) and DA (bottom panel) in brain regions. Male rats
received three i.p. injections of 1.5 or 7.5 mg/kg MDMA, one dose
every 2 h. Saline was administered on the same schedule. Rats were
killed 2 weeks after injections; brain regions were dissected, and
tissue 5-HT and DA were assayed by HPLC–ECD (Baumann et al.
2001). Data are mean±SEM expressed as the percentage of saline-
treated control values for each region, N=5 rats/group. Control
values of 5-HT and DA were 557±24 and 28±4 pg/mg tissue for
frontal cortex (CTX), 429±36 and 10,755±780 pg/mg tissue for
striatum (STR), and 1,174±114 and 4,545±426 pg/mg tissue
for olfactory tubercle (OT). Asterisk denotes significance compared
to saline-injected control for each region (P<0.05 Duncan’s)
414and thalamus at higher doses. Most of the staining in the
cortex was associated with degenerating axons and
terminals, but cell bodies were also stained. The collective
results show that administration of MDMA at sufficient
doses (i.e., >25 mg/kg) can cause neuronal damage, as
indicated by sensitive silver staining methods.
There are several key factors to consider when inter-
preting the effects of MDMA on silver staining in rat brain.
Most importantly, both of the cited studies employed
massive cumulative doses of MDMA ranging from 80 to
600 mg/kg. Based on the concept of effect scaling de-
scribed previously (see Table 3), the single injections of
MDMA administered by Commins et al. and Jensen et al.
are 16–100 times higher than a behaviorally relevant dose
of 1.5 mg/kg. At such extraordinary doses of MDMA,
excessive sympathetic activation and hyperthermia could
cause physiological dysregulation sufficient to elicit non-
specific neuropathy. The idea that high-dose MDMA
causes nonspecific neuronal damage is supported by the
observation that increases in silver staining are not con-
fined to 5-HT cells. Both studies noted the presence of
argyrophilic cell bodies in the cortex of MDMA-treated
rats, yet 5-HT cell bodies are not present in the cortex
(Steinbusch 1981). Furthermore, the pattern of MDMA-
induced silver staining, which is largely confined to the
frontoparietal cortex, does not correspond to the pattern of
5-HT innervation or the pattern of 5-HT depletions. Given
these findings, it seems feasible that increases in silver-
positive staining produced by high-dose MDMA do not
reflect 5-HT neurotoxicity per se.
Schmued (2003) used a novel histological stain, Fluoro-
Jade B, to examine neuronal damage produced by MDMA
administration in rats. Fluoro-Jade B is an anionic fluores-
cein derivative that selectively stains degenerating termi-
nals, axons, and cell bodies (Schmued and Hopkins 2000).
Male Sprague–Dawley rats received single i.p. injections
of 10–40 mg/kg MDMA and were killed 48 h later. After
10 mg/kg MDMA, only one of four rats exhibited Fluoro-
Jade staining in the cortex, and this rat experienced
significant hyperthermia at the time of treatment. At higher
doses of MDMA, most rats displayed Fluoro-Jade staining
in a variety of brain areas. For example, degenerating
pyramidal and nonpyramidal cells were stained in the
parietal cortex, while degenerating multipolar cells were
stained in the ventral thalamus. The findings with Fluoro-
Jade B indicate that sufficient doses of MDMA (i.e.,
>20 mg/kg) can produce neuronal degeneration. However,
analogous to the findings with silver staining methods,
many of the damaged cells identified by Fluoro-Jade B are
nonserotonergic, and the pattern of staining does not
overlap with the pattern of 5-HT deficits. Additionally,
neuronal degeneration was only found in rats that
experienced hyperthermia of >41°C, again suggesting an
important link between elevated body temperature and
adverse effects.
A universal reaction to damage in the CNS is hypertro-
phy of astrocytes, or “reactive gliosis” [reviewed by
O’Callaghan and Sriram (2005)]. This response is accom-
panied by enhanced expression of glial-specific structural
proteins such as, glial fibrillary acidic protein (GFAP).
O’Callaghan et al. (1995) have verified that a wide range
of neurotoxic chemicals increase the levels of GFAP in
rodent CNS, indicating this protein can be used as a
sensitive marker of neuronal damage. These investigators
(O’Callaghan and Miller 1993) carried out extensive
studies to evaluate the effects of MDMA administration
on GFAP expression in rat brain. Male Long–Evans rats
were treated twice daily with s.c. injections of 10–30mg/kg
MDMA for 7 days and were sacrificed 48 h after the last
dose. This high-dose regimen of MDMA did not alter the
expression of GFAP, even though 5-HT levels were
markedly reduced in the cortex, hippocampus, and stria-
tum. A separate group of rats received twice daily s.c.
injections of 75–150 mg/kg MDMA for 2 days, and these
rats were killed 48 h later. In response to these massive
doses of MDMA, levels of GFAP were significantly
elevated in various brain regions but these increases did not
correlate with the degree of 5-HT depletions. Finally, the
effects of MDMAwere compared to the effects of the 5-HT
neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT). At doses
of MDMA and 5,7-DHT which caused comparable 5-HT
depletions, only 5,7-DHT increased GFAP.
In a more recent study, Pubill et al. (2003) compared the
effects of MDMA and methamphetamine on SERT binding
and a number of glial-specific markers. Male Sprague–
Dawley rats received twice daily s.c. injections of 20 mg/kg
MDMA for 4 days, and were killed at 3 and 7 days post-
treatment. MDMA caused marked decreases in [
3H]-
Table 4 Effects of (±)-MDMA administration on markers of neuronal degeneration in rats
CNS marker Dosing regimen Survival interval Reference
Increased silver-positive staining in degenerating neurons 80 mg/kg, s.c., twice daily, 4 days 15–48 h Commins et al. (1987)
25–150 mg/kg, s.c., twice daily,
2 days
2 days Jensen et al. (1993)
Increased Fluoro-Jade B staining of degenerating neurons 20–40 mg/kg, i.p., single dose 2 days Schmued (2003)
Reactive astrogliosis as measured by elevations in GFAP 75–150 mg/kg, s.c., twice daily,
2 days
2 days O’Callaghan and Miller
(1993)
a
20 mg/kg, i.p., single dose 1 week Aguirre et al. (1999)
20 mg/kg, s.c., twice daily, 4 days 3 days, 1 week Pubill et al. (2003)
a
7.5 mg/kg, i.p., three doses 2 weeks Wang et al. (2004)
a
aThese investigators found no effect of MDMA on GFAP at doses which significantly depleted 5-HT levels in brain tissue
415paroxetine-labeled SERT binding but had no effect on any
measures of reactive gliosis. In particular, MDMA treat-
ment failed to induce astroglial activation as indicated by
the lack of changes in immunoreactive GFAP. MDMA had
no effect on microglial markers such as peripheral benzo-
diazepine receptors and OX-6 protein. Interestingly, meth-
amphetamine produced significant increases in astroglial
and microglial markers in this study, indicating an
important distinction between methamphetamine and
MDMA. Consistent with the findings of Pubill and
colleagues, Bai et al. (2001) found that 10 mg/kg s.c.
MDA failed to increase GFAP expression in Sprague–
Dawley rats. In contrast, Aguirre et al. (1999) reported that
a single i.p. dose of 20 mg/kg MDMA enhanced histo-
chemical staining for GFAP in the hippocampus of Wistar
rats. The reasons for the discrepancies between the findings
of Aguirre et al. vs the findings of others are not readily
apparent, but could be due to differences in experimental
methods across studies (i.e., different rat strains, different
brain regions examined, etc).
The majority of data indicate that doses of MDMA
causing significant 5-HT depletions (i.e., single or repeated
doses of 10–20 mg/kg) do not reliably induce silver
staining or glial activation. Recent results from our
laboratory support this assertion (Rothman et al. 2003;
Wang et al. 2004). We examined the possible neurotoxic
effects of MDMA and two other substituted amphetamines,
(+)-fenfluramine and p-chloroamphetamine (PCA). Spe-
cifically, the effects of drug treatments on the expression of
SERT and GFAP were evaluated using Western blot meth-
ods. In the first study, male Sprague–Dawley rats received
four i.p. injections of 6 mg/kg (+)-fenfluramine or one i.p.
injection of 5 mg/kg PCA, and rats were killed 2 days or
2 weeks thereafter. (+)-Fenfluramine and PCA decreased
cortical 5-HT levels (∼50–60%) but neither drug caused
long-term changes in the expression of SERT or GFAP
(Rothman et al. 2003). Similar results were found when
three i.p. injections of 7.5 mg/kg MDMA were adminis-
tered to rats according to the binge dosing regimen
described above (see Figs. 4 and 5). MDMA did not alter
levels of immunoreactive SERT or GFAP when examined
2 weeks after treatment, even though the same rats dis-
played substantial depletions of 5-HT in the cortex,
striatum, and hippocampus (Wang et al. 2004). Thus,
doses of MDMA that deplete tissue 5-HT do not alter
expression of SERT or GFAP. The SERT data are espe-
cially surprising given that MDMA administration is
known to reduce the number of SERT binding sites,
thereby decreasing [
3H]5-HT uptake capability (Battaglia
et al. 1987; Commins et al. 1987; Schmidt 1987).
To explore this phenomenon further, we compared the
effects of MDMA and 5,7-DHTon the expression of SERT,
GFAP, and other markers of gliosis (Wang et al. 2005). In
all cases, proteins were measured by Western blot analysis
using sensitive polyclonal antibodies directed against the
protein of interest. Sprague–Dawley rats received three i.p.
injections of 7.5 mg/kg MDMA or saline vehicle, and were
killed at 3 days and 2 weeks later. A separate group of rats
received single intracerebroventricular (i.c.v.) infusions of
150 μg 5,7-DHT or 0.1% ascorbic acid vehicle. Both
MDMA and 5,7-DHT caused 50–70% depletions of 5-HT
in the frontal cortex at 3 days and 2 weeks after treatments.
Figure 6 depicts previously published data from our
laboratory showing that MDMA does not affect tissue
levels of SERTat 2 weeks posttreatment, whereas 5,7-DHT
causes significant decreases in this protein (Wang et al.
2005). The data in Fig. 7 reveal that binge MDMA
treatment does not affect GFAP, while 5,7-DHT increases
levels of this protein. It should be mentioned that treatment
with 5,7-DHT, but not MDMA, produces persistent in-
creases in another astrocyte marker, heat shock protein 32.
On-going studies in our laboratory indicate that MDMA
does not alter the intracellular trafficking of SERT proteins
from endosomes to the plasma membrane (Wang et al.
2005). Rather, it seems that MDMA renders SERT proteins
nonfunctional, though the mechanism responsible for this
effect is not known. Our findings provide evidence that
5,7-DHT decreases SERT and increases GFAP, whereas
MDMA does not alter expression of either protein.
Accordingly, at the doses tested in these studies, 5,7-
DHT displays the profile of a 5-HT neurotoxin, whereas
MDMA does not.
Functional consequences of MDMA-induced 5-HT
depletion
Any operational definition of “neurotoxicity” must include
the precept that functional impairments accompany neuro-
nal damage (Moser 2000; Winneke and Lilienthal 1992).
As noted previously, high-dose MDMA causes persistent
inactivation of tryptophan hydroxylase, which leads to
inhibition of 5-HT synthesis and loss of 5-HT (O’Hearn et
al. 1988; Stone et al. 1987). Moreover, MDMA-induced
reduction in the density of SERT binding sites leads to
decreased capacity for 5-HT uptake in nervous tissue
(Battaglia et al. 1987; Schmidt 1987). Regardless of
whether these deficits reflect neurotoxic damage or long-
term adaptation, such changes would be expected to have
discernible in vivo correlates. Many investigators have
examined functional consequences of high-dose MDMA
administration, and a comprehensive review of this subject
is beyond the scope of the present paper [reviewed by Cole
and Sumnall 2003; Green et al. (2003)]. The following
discussion will consider long-term effects of MDMA (i.e.,
>1 week) on in vivo indicators of 5-HT function in rats, as
measured by electrophysiological recording, microdialysis
sampling, neuroendocrine secretion, and specific aspects of
behavior. A number of key findings are summarized in
Table 5. In general, few published studies have been able to
relate the magnitude of MDMA-induced 5-HT depletion to
the degree of specific functional impairment. Furthermore,
MDMA administration rarely causes persistent changes in
baseline measures of neural function, and deficits are most
readily demonstrated by provocation of the 5-HTsystem by
pharmacological (e.g., drug challenge) or physiological
means (e.g., environmental stress).
4165-HT projections innervating the rat forebrain have cell
bodies residing in the raphe nuclei (Steinbusch 1981).
These neurons exhibit pacemaker-like electrical activity,
which can be recorded using electrophysiological tech-
niques (Aghajanian et al. 1978; Sprouse et al. 1989).
Gartside et al. (1996) used extracellular recording methods
to examine 5-HT cell firing in the dorsal raphe of rats
previously treated with MDMA. Rats received two daily
injections of 20 mg/kg, s.c. MDMA for 4 days and were
tested under chloral hydrate anesthesia 2 weeks later.
MDMA pretreatment had no effect on the number of
classical or burst-firing 5-HT cells encountered during
recording. Additionally, 5-HT cell firing rates and action
potential characteristics were not different between
MDMA- and saline-pretreated groups. These data show
that 5-HT neurons and their firing properties are not altered
after MDMA administration, and this agrees with immu-
nohistochemical evidence demonstrating that MDMA does
not destroy 5-HT perikarya. The electrophysiological data
from MDMA-pretreated rats differ from the findings
reported with 5,7-DHT. In rats treated with i.c.v. 5,7-
DHT, the number of classical and burst-firing 5-HT
neurons is dramatically decreased in the dorsal raphe, in
conjunction with a loss of 5-HT fluorescence (Aghajanian
et al. 1978; Hajos and Sharp 1996). Thus, 5,7-DHT pro-
duces reductions in 5-HT cell firing that are attributable to
cell death, but MDMA does not.
In vivo microdialysis allows continuous sampling of
extracellular fluid from intact brain, and this method has
been used to evaluate persistent neurochemical conse-
quences of MDMA exposure (Gartside et al. 1996;
Matuszewich et al. 2002; Series et al. 1994; Shankaran
and Gudelsky 1999). Series et al. 1994 carried out
microdialysis in rat frontal cortex to examine long-term
effects of MDMA administration. Male Sprague–Dawley
rats received twice daily s.c. injections of 20 mg/kg
MDMA for 4 days, and were tested under chloral hydrate
anesthesia 2 weeks later. Prior MDMA exposure did not
Fig. 7 Comparative effects of (±)-MDMA (top panel) and 5,7-DHT
(bottom panel) on GFAP expression in dissected brain regions. One
group of rats received three i.p. injections of saline or 7.5 mg/kg
MDMA, one dose every 2 h. Another group received single i.c.v.
infusions of 5,7-DHT or vehicle. Rats were killed 2 weeks later and
brain regions were dissected. Western blot analysis of GFAP
immunoreactivity in the frontal cortex (CTX), striatum (STR), and
hippocampus (HIPP) was carried out as described (Wang et al.
2005). Blots were digitized and quantified using densitometry (NIH
IMAGE software). Changes in immunoreactivity are expressed
relative to their corresponding control (defined as 100% value).
Each value is the mean±SEM for N=4 rats/group. Asterisk denotes
significance with respect to control in each region (P<0.01 Student’s
t test). Data were taken from Wang et al. 2005
Fig. 6 Comparative effects of (±)-MDMA (top panel) and 5,7-DHT
(bottom panel) on SERT protein expression in dissected brain
regions. One group of rats received three i.p. injections of saline or
7.5 mg/kg MDMA, one dose every 2 h. Another group received
single i.c.v. infusions of 5,7-DHT or vehicle. Rats were killed
2 weeks later and brain regions were dissected. Western blot analysis
of SERT immunoreactivity in the frontal cortex (CTX), striatum
(STR), and hippocampus (HIPP) was carried out as described (Wang
et al. 2005). Blots were digitized and quantified using densitometry
(NIH IMAGE software). Changes in immunoreactivity are ex-
pressed relative to their corresponding control (defined as 100%
value). Each value is the mean±SEM for N=4 rats/group.
Asteriskdenotes significance with respect to control in each region
(P<0.01 Student’s t test). Data taken from Wang et al. 2005
417affect baseline extracellular levels of 5-HT, but levels of the
5-HT metabolite, 5-hydroxyindoleacetic acid (5-HIAA),
were decreased to ∼30% of control. Moreover, the ability
of (+)-fenfluramine (10 mg/kg, i.p.) to evoke 5-HT release
was markedly blunted in MDMA-pretreated rats when
compared to saline-pretreated controls. In an analogous
investigation, Shankaran and Gudelsky (1999) assessed
neurochemical effects of acute MDMA challenge in rats
that had previously received four i.p. injections of 10 mg/
kg MDMA. In vivo microdialysis was performed in the
striatum of conscious rats 1 week after high-dose MDMA
treatment. Baseline levels of dialysate 5-HT were not
altered by prior MDMA exposure, even though tissue
levels of 5-HT in striatum were depleted by 50%. The
ability of MDMA to evoke 5-HT release was severely
impaired in MDMA-pretreated rats, while the concurrent
DA response was normal. In this same study, effects of
MDMA on body temperature and 5-HT syndrome were
attenuated in MDMA-pretreated rats, suggesting the
development of tolerance. Other investigations using in
vivo microdialysis methods have shown that 5-HT release
in response to physiological or stressful stimuli is impaired
in rats pretreated with high-dose MDMA (Gartside et al.
1996; Matuszewich et al. 2002).
Taken together, the microdialysis studies reveal im-
portant long-term consequences of MDMA administration:
(1) baseline levels of dialysate 5-HTare not altered despite
depletions of tissue transmitter, (2) baseline levels of
dialysate 5-HIAA are consistently decreased, and (3)
stimulated release of 5-HT is blunted in response to
pharmacological or physiological provocation. The micro-
dialysis findings with MDMA resemble those obtained
from rats treated with 5,7-DHT, in which lesioned rats
display normal baseline dialysate 5-HT but decreased 5-
HIAA (Hall et al. 1999; Kirby et al. 1995; Romero et al.
1998). In a representative study, Kirby et al. (1995) used
microdialysis in rat striatum to evaluate the long-term
neurochemical effects of i.c.v. 5,7-DHT; these investigators
showed that reductions in dialysate 5-HIAA and impair-
ments in stimulated 5-HTrelease are highly correlated with
loss of tissue 5-HT, whereas baseline dialysate 5-HT is not.
In fact, depletions of brain tissue 5-HT up to 90% did not
affect baseline levels of dialysate 5-HT (Kirby et al. 1995).
It seems that adaptive mechanisms serve to maintain
normal concentrations of synaptic 5-HT, even under
conditions of severe transmitter depletion. A comparable
situation exists after lesions of the nigrostriatal DA system,
where baseline levels of extracellular DA are maintained in
the physiological range despite substantial loss of tissue
DA [see Zigmond et al. (1990)]. In the case of high-dose
MDMA treatment, it seems feasible that reductions in 5-
HT uptake (e.g., less functional SERT protein) and
metabolism (e.g., decreased monoamine oxidase activity)
compensate for 5-HT depletions to keep optimal concen-
trations of 5-HT bathing nerve cells. On the other hand,
deficits in 5-HT release are readily demonstrated in
MDMA-pretreated rats when 5-HT systems are taxed by
drug challenge or environmental stressors.
5-HT neurons projecting to the hypothalamus provide
stimulatory input for the secretion of adrenocorticotropin
(ACTH) and prolactin from the anterior pituitary (Van de
Kar 1991). Accordingly, 5-HT releasers (e.g., fenflur-
amine) and 5-HT receptor agonists increase plasma levels
of these hormones in rats and humans [reviewed by Levy et
al. (1994)]. Neuroendocrine challenge experiments have
been used to demonstrate changes in serotonergic respon-
siveness in rats treated with MDMA (Poland 1990; Poland
et al. 1997; Series et al. 1995). In the most comprehensive
study, Poland et al. (1997) examined effects of high-dose
MDMA on hormone responses elicited by acute fenflur-
amine challenge. Male Sprague–Dawley rats received
single s.c. injections of 20 mg/kg MDMA and were tested
2 weeks later. Prior MDMA exposure did not alter baseline
levels of circulating ACTH or prolactin. However, in
MDMA-pretreated rats, fenfluramine-induced ACTH se-
cretion was reduced, while prolactin secretion was
enhanced. The MDMA dosing regimen caused significant
depletions of tissue 5-HT in various brain regions, in-
cluding hypothalamus. In a follow-up time-course study,
rats received twice daily s.c. injections of 20 mg/kg
MDMA for 4 days, and were challenged with fenfluramine
(6 mg/kg, s.c.) at 4, 8, and 12 months thereafter. As
observed in the single dose MDMA study, rats exposed to
multiple MDMA doses displayed blunted ACTH responses
and augmented prolactin responses to fenfluramine.
Interestingly, the impaired ACTH response persisted for
Table 5 Effects of (±)-MDMA administration on functional indices of 5-HT transmission in rats
CNS effect Dosing regimen Survival interval Reference
No change in 5-HT cell firing 20 mg/kg, s.c., twice daily, 4 days 2 weeks Gartside et al. (1996)
Reductions in evoked 5-HT release
in vivo
20 mg/kg, s.c., twice daily, 4 days 2 weeks Series et al. (1994)
10 mg/kg, i.p., twice daily, 4 days 1 week Shankaran and Gudelsky (1999)
Changes in corticosterone and prolactin
secretion
20 mg/kg, s.c., single dose 2 weeks Poland et al. (1997)
20 mg/kg, s.c. twice daily, 4 days; 4, 8, and
12 months
Increased anxiety-like behaviors 5 mg/kg, s.c., 1 or four injections,
2 days
3 months McGregor et al. (2003)
a and Morley
et al. (2001)
7.5 mg/kg, sc, twice daily, 3 days 2 weeks Fone et al. (2002)
a
aThese investigators noted marked increases in anxiogenic behaviors in the absence of significant MDMA-induced 5-HT depletion in brain
41812 months in MDMA-pretreated rats, even though tissue
levels of 5-HT were not depleted at this time point. The
data show that high-dose MDMA can cause functional
abnormalities for up to 1 year, and changes in 5-HT re-
sponsiveness do not necessarily parallel the extent of
recovery from 5-HT depletions in brain.
In our laboratory, we wished to further explore the long-
term neuroendocrine consequences of MDMA administra-
tion. Utilizing the binge MDMA dosing regimen described
previously (see Figs. 4 and 5), male Sprague–Dawley rats
received three i.p. injections of 1.5 or 7.5 mg/kg MDMA,
one dose every 2 h. Control rats received saline vehicle
according to the same schedule. One week after MDMA
treatment, rats were fitted with indwelling jugular catheters
under pentobarbital anesthesia. After 1 week of recovery
from surgery (i.e., 2 weeks after MDMA or saline), rats
were brought into the testing room and i.v. catheters were
connected to extension tubes. Each rat received an i.v.
injection of 1 mg/kg MDMA at time zero, followed by an
injection of 3 mg/kg MDMA 60 min later. Blood samples
were withdrawn via the catheters immediately before and
30 min after each dose of MDMA. Plasma levels of
corticosterone and prolactin were measured by radioim-
munoassay methods (Baumann et al. 1998). Hormone data
were normalized to percentage of preinjection control and
analyzed using a two-way ANOVA (pretreatment × acute
treatment), followed by Duncan’s post hoc test. Figure 8
shows new data from our laboratory demonstrating the
effects of binge MDMA pretreatment on hormone re-
sponses examined 2 weeks later. MDMA pretreatment did
not alter baseline levels of either hormone. Acute admin-
istration of MDMA elicited dose-related elevations in
circulating corticosterone (F2,63=62.03, P<0.0001) and
prolactin (F2,63=45.41, P<0.0001) as shown by others
(Nash et al. 1988). Importantly, MDMA pretreatment
significantly attenuated MDMA-induced corticosterone
(F2,63=6.89, P<0.01) and prolactin (F2,63=8.30, P<0.001)
responses. Post hoc tests revealed that rats exposed to high-
dose MDMA pretreatment displayed reductions in corti-
costerone and prolactin secretion in response to acute
MDMA challenge, whereas hormone responses in the low-
dose MDMA rats were indistinguishable from controls.
Our neuroendocrine results are consistent with the
development of tolerance to hormonal effects of MDMA.
These findings do not agree completely with the data of
Poland et al. (1997) discussed above; however, our
findings do agree with previous data showing blunted
hormonal responses to fenfluramine in rats with fenflur-
amine-induced 5-HT depletions (Baumann et al. 1998).
Perhaps more importantly, the data shown in Fig. 8 are
strikingly similar to clinical findings in which cortisol and
prolactin responses to acute (+)-fenfluramine administra-
tion are reduced in human MDMA users (Gerra et al. 1998,
2000; Gouzoulis-Mayfrank et al. 2002). Indeed, Gerra et al.
(2000) reported that (+)-fenfluramine-induced prolactin
secretion is blunted in abstinent MDMA users for up to
1 year after cessation of drug use. The mechanism(s)
underlying reduced sensitivity to (+)-fenfluramine and
MDMA are not known, but it is tempting to speculate that
MDMA-induced impairments in evoked 5-HT release are
involved, as shown by in vivo microdialysis studies. While
some investigators have cited neuroendocrine changes in
human MDMA users as evidence for 5-HT neurotoxicity,
Gouzoulis-Mayfrank et al. (2002) provide a compelling
argument that endocrine abnormalities in MDMA users
could be related to cannabis use rather than MDMA.
Further experiments will be required to resolve the precise
nature of neuroendocrine changes in MDMA users.
One of the more serious and disturbing clinical findings
is that MDMA causes persistent cognitive deficits in some
users (Morgan 2000; Reneman 2003). Numerous research
groups have examined the effects of MDMA treatment on
learning and memory processes in rats, yet most studies
failed to identify persistent impairments, even when ex-
tensive 5-HT depletions were present (Byrne et al. 2000;
McNamara et al. 1995; Ricaurte et al. 1993; Robinson et al.
Fig. 8 Effects of (±)-MDMA pretreatment on secretion of cortico-
sterone (top panel) and prolactin (bottom panel) evoked by acute
(±)-MDMA challenge. Male rats received three i.p. injections of 1.5
or 7.5 mg/kg MDMA, one dose every 2 h. Saline was administered
on the same schedule. Two weeks later, each rat received a single i.v.
injection of 1 mg/kg MDMA at time zero, followed by a single
injection of 3 mg/kg MDMA 60 min later. Blood samples were
drawn via indwelling catheters immediately before injections and
30 min after each injection; plasma corticosterone and prolactin
were measured by RIA (Baumann et al. 1998). Data are mean±SEM
expressed as the percentage of baseline hormone levels for N=8 rats/
group. Baseline corticosterone and prolactin levels were 73±18 and
2.4±0.6 ng/ml of plasma, respectively. Asterisk denotes significance
compared to saline-pretreated control group (P<0.05 Duncan’s)
4191993; Seiden et al. 1993; Slikker et al. 1989). While an
exhaustive review of this literature is not possible here,
representative findings will be mentioned. In an extensive
series of experiments, Seiden et al. (1993) evaluated the
effects of high-dose MDMA on a battery of tests including
open-field behavior, schedule-controlled behavior, one-
way avoidance, discriminated two-way avoidance, forced
swim, and radial maze performance. Male Sprague–
Dawley rats received twice daily s.c. injections of 10–40
mg/kg MDMA for 4 days and were tested beginning
2 weeks after treatment. Despite large depletions of brain
tissue 5-HT, MDMA-pretreated rats exhibited normal
behaviors in all paradigms. Likewise, Robinson et al.
(1993) found that MDMA-induced depletion of cortical
5-HT up to 70% did not alter spatial navigation, skilled
forelimb use, or foraging behavior in rats. On the other
hand, Marston et al. (1999) reported that MDMA admin-
istration produces persistent deficits in a delayed nonmatch
to performance (DNMTP) procedure when long delay
intervals are employed (i.e., 30 s). Specifically, saline-
pretreated rats exhibited progressive improvement in task
performance over successive days of testing, whereas
MDMA-pretreated rats did not. The authors theorized that
delay-dependent impairments in the DNMTP procedure
reflect MDMA-induced deficits in short-term memory,
possibly attributable to 5-HT depletion.
With the exception of the findings of Marston et al., the
collective behavioral data in rats indicate that MDMA-
induced depletions of brain 5-HT have little effect on
cognitive processes. There are several potential explana-
tions for this apparent paradox. First, high-dose MDMA
administration produces only partial depletion of 5-HT in
the range of 40–60% in most brain areas. This level of
5-HT loss may not be sufficient to elicit behavioral alter-
ations, as compensatory adaptations in 5-HT neurons could
maintain normal physiological function. Second, MDMA
appears to selectively affect fine diameter fibers arising
from the dorsal raphe, and it is possible that these 5-HT
circuits may not subserve the behaviors being monitored.
Third, the behavioral tests utilized in rat studies might not
be sensitive enough to detect subtle changes in learning and
memory processes. Finally, the functional reserve capacity
in the CNS mightbe sufficient to compensate for even large
depletions of a single transmitter.
While MDMA appears to have few long-term effects on
cognition in rats, a growing body of evidence demonstrates
that MDMA administration can cause persistent anxiety-
like behaviors in this species (Fone et al. 2002; Gurtman et
al. 2002; Morley et al. 2001). Morley et al. (2001) first
reported that MDMA exposure induces long-term anxiety
in rats. These investigators gave male Wistar rats one or
four i.p. injections of 5 mg/kg MDMA for two consecutive
days. Subjects were tested 3 months later in a battery of
anxiety-related paradigms, including elevated plus maze,
emergence, and social interaction tests. Rats receiving
either single or multiple MDMA injections displayed
marked increases in anxiogenic behaviors in all three tests
when compared to control rats. Because no 5-HTendpoints
were examined, it was impossible to relate changes in
behavior to changes in 5-HT transmission. In a follow-up
study, Gurtman et al. (2002) replicated the original findings
of Morley et al. using rats pretreated with four i.p.
injections of 5 mg/kg MDMA for 2 days; persistent anxio-
genic effects of MDMAwere associated with depletions of
5-HT in the amygdala, hippocampus, and striatum.
Interestingly, Fone et al. (2002) showed that twice daily
injections of 7.5 mg/kg MDMA for 3 days caused im-
pairments in social interaction in adolescent Lister rats,
even in the absence of 5-HT depletions or reductions in
[
3H]-paroxetine-labeled SERT binding sites. These data
suggested the possibility that MDMA-induced anxiety
does not require 5-HT deficits.
In an attempt to determine potential mechanisms under-
lying MDMA-induced anxiety, McGregor et al. (2003)
evaluated effects of the drug on anxiety-related behaviors
and a number of postmortem parameters including auto-
radiography for SERT and 5-HT receptor subtypes. Rats
received moderate (5 mg/kg, i.p., 2 days) or high (5 mg/kg,
i.p., four injections, 2 days) doses of MDMA, and tests
were conducted 10 weeks later. This study confirmed that
moderate doses of MDMA could cause protracted in-
creases in anxiety-like behaviors without significant 5-HT
depletions. Furthermore, the autoradiographic analysis
revealed that anxiogenic effects of MDMA may involve
long-term reductions in 5-HT2A/2C receptors, rather than
reductions in SERT binding. Additional work by Bull et al.
(2003, 2004) suggests that decreases in the sensitivity of
5-HT2A receptors, but not 5-HT2C receptors, could underlie
MDMA-associated anxiety. Clearly, more investigation
into this important area of research is warranted.
Summary
The findings reviewed in this paper allow a number of
conclusions to be drawn with regard to MDMA-induced
neurotoxicity. First, there is little doubt that MDMA targets
monoamine transporters, and transporter-mediated release
of 5-HT, DA, and NE underlies pharmacological effects of
the drug. While MDMA has been considered a predomi-
nately serotonergic agent, certain adverse effects including
cardiovascular stimulation and hyperthermia likely involve
NE and DA mechanisms, respectively. There seems to be
no scientific rationale for using allometric scaling to adjust
doses of MDMA between rats and humans because the
pharmacologically relevant doses are similar in both
species (e.g., 1–2 mg/kg). Nonetheless, the complex
metabolism of MDMA needs to be examined in various
animal species to permit comparison with clinical literature
and to validate appropriate preclinical models. With regard
to MDMA-induced neurotoxicity, it seems that 5-HT
deficits are not always synonymous with axonal death
because doses of MDMA which cause marked depletions
of brain tissue 5-HT in rats (e.g., 10–20 mg/kg) are not
associated with silver-positive staining, reactive gliosis, or
loss of SERT protein. Like many other psychotropic drugs,
MDMA is capable of producing bona fide neurotoxicity at
sufficient doses (e.g., >25 mg/kg), and damage is not
420confined to 5-HT neurons. Many aspects of 5-HT function
appear to be normal in MDMA-pretreated rats despite sig-
nificant loss of brain 5-HT, perhaps illustrating the pro-
found adaptive capability of the CNS. On the other hand,
MDMA-induced 5-HT depletions are accompanied by
impairments in evoked 5-HT release and neuroendocrine
secretion that suggest tolerance development. The clinical
relevance of preclinical findings is often uncertain, but the
fact that MDMA can produce persistent increases in
anxiety-like behaviors without measurable 5-HT deficits
suggests that even moderate doses may pose risks.
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